NTHI NEONC TECHNOLOGIES HOLDINGS, INC.
Price Chart
Executive Summary
NeOnc reported Q1 2026 net loss of $8.8M (-$0.38/sh) vs consensus -$0.30, a 26.7% miss, but this is typical for pre-revenue biotechs. Operationally, NEO212 Phase 1 completed with RP2D set, NEO100 Phase 2a fully enrolled with data in Aug 2026, CEO bought >$500k shares, and $10M PIPE + undrawn LOC fund ops into Sep 2026. The stock may trade range-bound near-term with catalyst-driven upside potential.
Actionable Insight
Traders should watch for the NEO100 interim data readout (~Aug 2026) and NEO212 FDA meeting outcome as key catalysts. Cash runway is tight through Sep 2026, but the PIPE and LOC provide a cushion; any delay in clinical milestones could pressure the stock. CEO insider buying offers some support.
Key Facts
- Q1 2026 net loss $8.8M vs $32.3M in Q1 2025, improvement driven by lower stock-based compensation and advisory fees.
- EPS of -$0.38 missed consensus of -$0.30 (26.7% miss).
- Cash and equivalents $138,601 as of March 31, 2026, supplemented by $10M PIPE commitment and $10M undrawn LOC.
- NEO212 Phase 1 complete, RP2D 610 mg, planning Type B End-of-Phase 1 FDA meeting.
- NEO100 Phase 2a fully enrolled for IDH1-mutant HGG, interim data readout expected ~August 2026.
- CEO Amir Heshmatpour purchased >$500k of NTHI shares in open market.
- Normalized cash operating expenses ~$6.1M for Q1 ($24.4M annualized).
Financial Impact
EPS miss of -26.7% vs consensus, but pre-revenue stage; net loss improved 73% YoY to $8.8M.
Risk Factors
- Cash runway only until September 2026; potential dilution from follow-on financing if milestones slip.
- Clinical trial risks: NEO100/NEO212 may fail to show efficacy in larger cohorts.
- EPS miss may weigh on sentiment in the near term given high expectations.
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-005421 |
| Document: neonctechnologies_ex99-1.htm | 0001829126-26-005421 |
| Document: 0001829126-26-005421-index-headers.html | 0001829126-26-005421 |
| Document: 0001829126-26-005421-index.html | 0001829126-26-005421 |
| Document: 0001829126-26-005421.txt | 0001829126-26-005421 |
| 8-K Data (Synthetic) | 0001829126-26-005421 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
1d ago
|
8-K
| $4.55 awaiting T+5 | awaiting T+5 | — | $4.75 (−4.40%) |
|
May 18, 2026
25d ago
|
8-K
| $5.48 $4.84 | ▼ −11.77% | ▼ −14.07% | $4.75 (−13.32%) |
|
May 18, 2026
25d ago
|
Press Release
| $5.34 $5.14 | ▲ +3.75% | ▲ +5.36% | $4.75 (+11.05%) |
|
May 5, 2026
5w ago
|
10-K/A
| $4.99 $5.51 | ▲ +10.42% | ▲ +8.44% | $4.75 (−4.81%) |
|
Apr 24, 2026
7w ago
|
8-K
| $4.61 $4.14 | ▲ +10.20% | ▲ +10.60% | $4.75 (−3.04%) |
|
Apr 23, 2026
7w ago
|
Insider Cluster
| $4.30 $5.31 | ▲ +23.49% | ▲ +20.38% | $4.75 (+10.47%) |
|
Apr 23, 2026
7w ago
|
Insider Cluster
| $4.79 $4.30 | ▼ −10.23% | ▼ −11.71% | $4.75 (−0.84%) |
|
Apr 17, 2026
8w ago
|
EFFECT
| $5.34 $4.78 | ▼ −10.49% | ▼ −11.04% | $4.75 (−11.05%) |
|
Apr 16, 2026
8w ago
|
8-K
| $5.34 $4.78 | ▼ −10.49% | ▼ −11.04% | $4.75 (−11.05%) |
|
Apr 16, 2026
8w ago
|
424B5
| $5.34 $4.78 | ▲ +10.49% | ▲ +11.04% | $4.75 (+11.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access